Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
galeterone hydrochloride + IET
- Development stage
- Unknown
- Lead developer
- LTN Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Galeterone hydrochloride + IET is an investigational drug product being developed by LTN Pharmaceuticals for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It consists of galeterone hydrochloride, a multi-targeted small molecule, combined with a proprietary Improved Exposure Technology (IET) designed to optimize the drug's pharmacokinetic profile and oral bioavailability. Galeterone acts through a triple mechanism of action: it serves as a selective androgen receptor (AR) antagonist, a CYP17 enzyme inhibitor (blocking androgen synthesis), and an AR degrader that specifically targets both wild-type AR and the AR-V7 splice variant, which is associated with resistance to standard therapies. The program is currently in Phase 2 clinical development, focusing on addressing the limitations of earlier galeterone formulations.
- Other names
- Galeterone HCl + IETGaleterone hydrochloride + Improved Exposure Technology
02
Targets
USP12/USP46 (Ubiquitin-specific peptidases 12 and 46)AR (Adrenergic receptors)CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)
Beyond the preview
Go deeper on galeterone hydrochloride + IET.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on galeterone hydrochloride + IET.